Gemcitabine-(C$_4$-amide)-[anti-HER2/neu] Anti-Neoplastic Cytotoxicity in Dual Combination with Mebendazole against Chemotherapeutic-Resistant Mammary Adenocarcinoma

C.P. Coyne*1, Toni Jones1 and Ryan Bear2

Abstract

Introduction: Gemcitabine is a pyrimidine nucleoside analog that becomes phosphorylated and competitively inhibits cytidine incorporation into DNA strands. Diphosphorylated gemcitabine irreversibly inhibits ribonucleotide reductase thereby preventing deoxynucleobonucleotide synthesis. Functioning as a potent chemotherapeutic, gemcitabine decreases neoplastic cell proliferation and induces apoptosis which accounts for its effectiveness in the clinical treatment of several leukemia and carcinoma cell types. A brief plasma half-life due to rapid deamination, chemotherapeutic-resistance and sequela restrict gemcitabine utility in clinical oncology. Selective “targeted” gemcitabine delivery represents a molecular strategy for prolonging its plasma half-life and minimizing innocent tissue/organ exposure.

Methods: A previously described organic chemistry scheme was applied to synthesize a UV-photoactivated gemcitabine intermediate for production of gemcitabine-(C$_4$-amide)-[anti-HER2/neu]. Immunodetection analysis (Western-blot) was applied to detect the presence of any degradative fragmentation or polymerization. Detection of retained binding-avidity of gemcitabine-(C$_4$-amide)-[anti-HER2/neu] was determined by cell-ELISA using populations of chemotherapeutic-resistant mammary adenocarcinoma (SKBr-3) that highly over-express the HER2/neu trophic membrane receptor. Cytotoxic anti-neoplastic potency of gemcitabine-(C$_4$-amide)-[anti-HER2/neu] and the benzimidazole tubulin/microtubule inhibitors, albendazole, flubendazole and mebendazole was established against chemotherapeutic-resistant mammary adenocarcinoma (SKBr-3). Related investigations evaluated the potential for gemcitabine-(C$_4$-amide)-[anti-HER2/neu] in dual combination with mebendazole to evoke increased levels of cytotoxic anti-neoplastic potency compared to gemcitabine-(C$_4$-amide)-[anti-HER2/neu].

Results: Covalent gemcitabine-(C$_4$-amide)-[anti-HER2/neu] immunochemotherapeutic and each benzimidazole (n=5) exerted cytotoxic anti-neoplastic potency against chemotherapeutic-resistant mammary adenocarcinoma.

Conclusion: Gemcitabine-(C$_4$-amide)-[anti-HER2/neu] in dual combination with benzimidazoles can produce enhanced levels of cytotoxic anti-neoplastic activity and potentially provide a basis for treatment regimens with a wider margin-of-safety. Such benefits would be possible through the collective properties of; [i] selective ‘targeted’ gemcitabine delivery; [ii] relatively lower toxicity of benzimidazoles compared to many if not most conventional chemotherapeutics; [iii] reduced total dosage requirements facilitated by additive or synergistic anti-cancer properties; and [iv] differences in sequela for gemcitabine-(C$_4$-amide)-[anti-HER2/neu] compared to benzimidazole tubulin/microtubule inhibitors.

Keywords

Anti-HER2/neu; Benzimidazoles; Chemotherapeutic-resistant; Covalent immunochemotherapeutic; Cytotoxic anti-neoplastic potency; Dual combination anti-cancer therapy; Gemcitabine-(C$_4$-amide)-[anti-HER2/neu]; Mammary adenocarcinoma

Abbreviation

HER2/neu: trophic membrane receptor complex over-expressed by several neoplastic cell types

Introduction

Monoclonal immunoglobulin preparations or pharmaceuticals with binding-avidity for HER2/neu (e.g. anti-HER2/neu: trastuzumab, pertuzumab) [1-5] EGFR (e.g. anti-EGFR: cetuximab, gefitinib) [6-9] immunoglobulin fractions with dual binding-avidity for both HER2/neu and EGFR (e.g. anti-HER2/neu and anti-EGFR properties: panitumumab) [8-11] or monoclonal immunoglobulin inhibitors of other trophic receptors can all be effective treatment options for cancer including forms affecting the breast, intestinal tract, lung and prostate. The obvious advantage of these preparations is their ability to function as an anti-cancer treatment modality that avoids many of the sequelae associated with conventional chemotherapeutics. Unfortunately, most monoclonal immunoglobulin-based therapies that inhibit trophic membrane receptor function are usually only capable of promoting cytostatic properties and are almost invariably plagued by an inability to evoke cytotoxic activity sufficient to effectively resolve most advanced or aggressive forms of neoplastic disease [12-17].

The anthracyclines have traditionally been the class of chemotherapeutics most commonly bonded covalently to (large) molecular platforms that can facilitate “selective” targeted delivery. Gemcitabine, in contrast to the anthracyclines, is a chemotherapeutic that has less frequently been covalently bound to large molecular weight platforms that can provide various biological properties [18,19] including selective “targeted” delivery [20] Gemcitabine is a deoxyctidine nucleotide analog with a mechanism-of-action that is dependent upon intracellular triphosphoralation which allows it to
substitute for cytidine during DNA transcription. In this capacity triphosphorlated gemcitabine both inhibits DNA polymerase biochemical activity and is incorporated into DNA strands. A second mechanism-of-action involves gemcitabine inhibiting and inactivating ribonucleotide reductase in concert with suppression of deoxyribonucleotide synthesis, diminished DNA repair and declines in DNA transcription. Each of these mechanisms-of-action induces the onset of apoptosis. In clinical oncology, gemcitabine is administered for the treatment of certain leukemias and potentially different types of lymphoma in addition to a spectrum of adenocarcinomas and carcinomas affecting the lung (e.g. non-small cell), pancreas, bladder and esophagus. The plasma half-life for gemcitabine is brief because it is rapidly deaminated to an inactive metabolite that is then readily eliminated through renal excretion into the urine [21-23].

Several distinct attributes can be realized through the molecular design and organic chemistry synthesis of a covalent gemcitabine immunochemotherapeutic that in part include the properties of selective “targeted” chemotherapeutic delivery, continual deposition, progressive intracellular accumulation, and extended plasma gemcitabine pharmacokinetic profile. Presumably due steric hinderance phenomenon, gemcitabine covalently bound to large molecular weight platforms like immunoglobulin is less vulnerable to MDR-1 (multi-drug resistance efflux pump) [24], or biochemical deamination by cytidine deaminase and deoxycytidylate deaminase (following gemcitabine phosphorylation). Complementary advantages of covalently bonding gemcitabine to immunoglobulin or molecular ligands are the obvious opportunity they afford to evoke additive or synergistic levels of cytotoxic anti-neoplastic potency. In this regard, anti-HER2/neu, anti-EGFR and similar monoclonal immunoglobulin fractions provide a mechanism for simultaneously achieving selective “targeted” chemotherapeutic delivery and suppression of neoplastic cell biological vitality in populations that are heavily dependent on trophic receptor over-expression.

Gemcitabine in clinical scenarios is frequently administered in combination with tubulin/microtubule inhibitor chemotherapeutics includingvinca alkaloids [25-28]taxanes [28-30]podophyllotoxins/etoposides [31-33] and monomethyl auristatin E (MMAE) [34]. Such combinations have commonly been administered for the therapeutic management of neoplastic conditions affecting the breast [25-28,29] pancreas [33] lung [31] in addition to lymphoproliferative disorders [34]. Clinical trials have been conducted to evaluate the efficacy of gemcitabine in combination with vinca alkaloid (2010: sarcomas) and Brentuximab Vedotin (2011: anaplastic large cell lymphoma and Hodgkin’s Lymphoma). The benzimidazole anthelmintic agents functionally have a mechanism-of-action highly analogous to the vinca alkaloids and other tubulin/microtubule inhibitor chemotherapeutics. Given this perspective, benzimidazoles individually and mebendazole in dual combination with covalent gemcitabine-(C4-amide)-[anti-HER2/neu] immunochemotherapeutic were accessed for their individual and combined cytotoxic anti-neoplastic potency against chemotherapeutic-resistant mammary adenocarcinoma (SKBr-3) due to their potential for achieving additive or synergistic levels of efficacy.

Materials and Methods

Synthesis of covalent Gemcitabine-(C4-amide)-[anti-HER2/neu] Immunochemotherapeutic

Phase-I Synthesis Scheme for UV-Photoactivated Gemcitabine-(C4-amide) Intermediate: The cytosine-like C4-amino of gemcitabine (0.738 mg, 2.80 x 10^{-3} moles) was reacted at a 2.5:1 molar-ratio with the amine-reactive N-hydroxysuccinimide ester “leaving” complex of succinimidyl 4,4-azipentanoate (0.252 mg, 1.12 x 10^{-3} moles) in the presence of triethylamine (TEA 50 mM final concentration) utilizing dimethylsulfoxide as an organic solvent system (Figure 1). The reaction mixture of gemcitabine and succinimidyl 4,4-azipentanoate was continually stirred at 25°C for 4-hours in the dark.

Phase-II Synthesis Scheme for Covalent Gemcitabine-(C4-amide)-[anti-HER2/neu] Immunochemotherapeutic Utilizing a UV-Photoactivated Gemcitabine Intermediate: Immunoglobulin fractions of anti-HER2/neu (1.5 mg, 1.0 x 10^{-4} moles) in buffer (PBS: phosphate 0.1, NaCl 0.15 M, EDTA 10 mM, pH 7.3) were combined at a 1:10 molar-ratio with the UV-photoactivated gemcitabine-(C4-amide) intermediate (Phase-I end product) and allowed to gently mix by constant stirring for 5 minutes at 25°C in the dark. The photoactivated group of the gemcitabine-(C4-amide) intermediate was reacted with side chains of amino acid residues within the sequence of anti-HER2/neu monoclonal immunoglobulin during a 15 minute exposure to UV light at 354 nm (reagent activation range 320-370 nm) in combination with constant gentle stirring (Figure 1). Residual gemcitabine was removed from gemcitabine-(C4-amide)-[anti-HER2/neu] applying micro-scale column chromatography following pre-equilibration of exchange media with PBS (phosphate 0.1, NaCl 0.15 M, pH 7.3).

Analytical characterization:

General analyses: Approximation of the amount of non-covalently bound gemcitabine contained within the covalent gemcitabine-(C4-amide)-[anti-HER2/neu] immunochemotherapeutic following separation by column chromatography was determined by measuring absorbance at 265-267 nm [35,36] of the resulting supernatant after precipitation of gemcitabine-immunochemotherapeutics with either chloroform [37-39] or methanol:acetonitrile (1:9 v/v) with measurements compared to original known concentrations [40]. Determination of the immunoglobulin concentration for the covalent gemcitabine-(C4-amide)-[anti-HER2/neu] immunoconjugates was determined by measuring absorbance at 280 nm in combinations with utilizing a 235 nm -vs- 280 nm standardized reference curve in order to accommodate for any potential absorption profile over-lap at 280 nm between gemcitabine and immunoglobulin [20,40-44].

![Figure 1](https://example.com/figure1.png)  
**Figure 1:** Schematic illustration of the molecular design and chemical structure of the covalent immunochemotherapeutic, gemcitabine-(C4-amide)-[anti-HER2/neu] synthesized utilizing a 2-stage organic chemistry reaction scheme that initially generates a gemcitabine UV-photoactivated intermediate.
Molecular mass/size-dependent separation by non-reducing SDS-PAGE: The covalent gemcitabine-(C$_2$-amide)-[anti-HER2/neu] immunochemotherapeutic and anti-HER2/neu immunoglobulin reference control were adjusted to a standardized protein concentration of 60 µg/ml and then combined 50/50 v/v with conventional SDS-PAGE sample preparation buffer (Tris/glycerol/ bromophenyl blue/SDS) formulated without 2-mercaptoethanol or boiling. Each covalent immunochemotherapeutic, the reference control immunoglobulin fraction (0.9 µg/ml) and a mixture of pre-stained reference control molecular weight markers were then developed by SDS-PAGE (11% acrylamide) at 100 V constant voltage at 3°C for 2.5 hours.

Western-blot immunodetection: Covalent gemcitabine-(C$_2$-amide)-[anti-HER2/neu] immunochemotherapeutic following SDS-PAGE was equilibrated in tank buffer devoid of methanol. Mass/size-separated gemcitabine anti-HER2/neu immunochemotherapeutic contained in acrylamide SDS-PAGE gels was then transferred laterally onto nitrocellulose membrane at 20 volts (constant voltage) for 16 hours at 2°C to 3°C with the transfer manifold packed in crushed ice. Nitrocellulose membranes with laterally-transferred immunochemotherapeutics were then equilibrated in Tris buffered saline (TBS: Tris HCl 0.1 M, NaCl 150 mM, pH 7.5, 40 ml) at 4°C for 15 minutes followed by incubation in TBS blocking buffer solution (Tris 0.1 M, pH 7.4, 40 ml) containing bovine serum albumin (5%) for 16 hours at 2°C to 3°C applied in combination with gentle horizontal agitation. Prior to further processing, nitrocellulose membranes were vigorously rinsed in Tris buffered saline (Tris 0.1 M, pH 7.4, 40 ml, n=3x).

Rinsed BSA-blocked nitrocellulose membranes developed for Western-blot (immunodetection) analyses were incubated with biotinylated goat anti-murine IgG (1:10,000 dilution) at 4°C for 18 hours applied in combination with gentle horizontal agitation. Nitrocellulose membranes were then vigorously rinsed in TBS (pH 7.4, 4°C, 50 ml, n=3) followed by incubation in blocking buffer (Tris 0.1 M, pH 7.4, with BSA 5%, 40 ml). Blocking buffer was decanted from nitrocellulose membrane blots and then rinsed in TBS (pH 7.4, 4°C, 50 ml, n=3) before incubation with either strepavidin-HRPO or strepavidin-β-galactosidase conjugated goat anti-mouse IgG (1:500 dilution) for 2 hours at 25°C with residual unbound immunoglobulin removed by serial rinsing with PBS (n=3). Final cell ELISA development required serial rinsings (n=3) of stabilized mammary adenocarcinoma (SKBr-3) monolayers entailed incubation with β-galactosidase conjugated goat anti-mouse IgG (1:500 dilution) for 2 hours at 25°C with residual unbound immunoglobulin removed by serial rinsing with PBS (n=3). Final cell ELISA development required serial rinsings (n=3) of stabilized mammary adenocarcinoma (SKBr-3) monolayer populations with PBS followed by incubation with nitrophenyl-β-D-galactopyranoside substrate (100 µl/well of ONPG formulated fresh at 0.9 mg/ml in PBS pH 7.2 containing Mgc1, 10 mM, and 2-mercaptoethanol 0.1 M). Absorbance within each individual well was measured at 410 nm (630 nm reference wavelength) after incubation at 37°C for a period of 15 minutes.

Cell viability assay for anti-neoplastic cytotoxicity: Covalent gemcitabine-(C$_2$-amide)-[anti-HER2/neu] immunochemotherapeutic was formulated in growth media at chemotherapeutic-equivalent concentrations of 10$^{-6}$, 10$^{-5}$, 10$^{-4}$, and 10$^{-3}$ M. Similarly, abedozole, flubendazole and mebendazole were individually formulated in growth media at benzimidazole-equivalent concentrations of 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.75, 1.0, 2.0 and 2.5 µM. The covalent immunochemotherapeutic or individual benzimidazole was then transferred in triplicate into 96-well microtiter plates containing mammary adenocarcinoma (SKBr-3) monolayers (growth media 200 µl/well and allowed to incubate in direct contact with cell populations for either 72 or 182-hours (37°C under a gas atmosphere of air 95% and carbon dioxide (CO$_2$) 5%). Incubation periods of greater than 96-hours required replenishing mammary adenocarcinoma (SKBr-3) populations with fresh tissue culture media formulated with or without covalent gemcitabine-immunochemotherapeutics or benzimidazole tubulin/microtubule inhibitors as indicated.

Cytotoxic potency of gemcitabine-(C$_2$-amide)-[anti-HER2/neu] or the benzimidazoles was measured by removing all contents within the 96-well microtiter plates manually by pipette followed by serial rinsing of monolayers (n=3) with PBS and then incubated with 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide formulated in RPMI-1640 growth media devoid of pH indicator or bovine fetal calf serum (MTT: 5 mg/ml). During a 3 to 4 hour incubation period at 37°C under a gas atmosphere of air (95%) and carbon dioxide (5% CO$_2$) the enzyme mitochondrial succinate dehydrogenase was allowed to convert MTT vital stain reagent to navy-blue formazone crystals within the cytosol of mammary adenocarcinoma (SKBr-3) populations (some reports suggest that...
NADH/NADPH-dependent cellular oxidoreductase enzymes may also be involved in the conversion process. Contents of the 96-well microtiter plate were then removed and the stabilized monolayers serially rinsed with PBS (n=3). The resulting blue intracellular formazone crystals were dissolved with DMSO (300 μl/well) and then spectrophotometric absorbance of the blue-colored supernantant measured at 570 nm using a computer integrated microtiter plate reader.

Results

Molar-incorporation-index

Size-separation of gemcitabine-(C₄-amide)-[anti-HER2/neu] by micro-scale column chromatography consistently yielded a covalent immunochemotherapeutic preparation that contained <4.0% of residual non-covalently bound chemotherapeutic [20,40-44]. Small residual amounts of non-covalently bound chemotherapeutic remaining within covalent immunochemotherapeutic preparations is generally accepted to not be available for further removal through additional column chromatography separations [45] which closely correlates with results from previous investigations devoted to the molecular design and organic chemistry synthesis of similar covalent immunochemotherapeutics (unpublished data) [9,40-44]. Calculations estimated a 2.78 molar-incorporation index for covalent gemcitabine-(C₄-amide)-[anti-HER2/neu] immunochemotherapeutic.

Molecular weight profile analysis

Mass/size separation of covalent gemcitabine-(C₄-amide)-[anti-HER2/neu] immunochemotherapeutic by SDS-PAGE in combination with immunodetection analysis (Western blot) and chemiluminescent autoradiography recognized a single primary condensed band of 150-kDa between a molecular weight range of 5.0-kDa to 450-kDa (Figure 2). Patterns of low-molecular-weight fragmentation from hydrolytic or enzymatic degradation, or evidence of large-molecular-weight polymerization of immunoglobulin fractions were not detected (Figure 2). The observed molecular weight of 150-kDa for gemcitabine-(C₄-amide)-[anti-HER2/neu] directly corresponds with the known molecular weight/mass of reference control anti-HER2/neu monoclonal immunoglobulin fractions (Figure 2). Analogous results have been reported for similar covalent immunochemotherapeutics [40-44,46,47].

Cell-binding analysis

Total cell-bound immunoglobulin in the form of gemcitabine-(C₄-amide)-[anti-HER2/neu] on the external surface membrane of adherent mammary adenocarcinoma (SKBr-3) populations was measured by cell-ELISA (Figure 3). Greater total membrane-bound gemcitabine-(C₄-amide)-[anti-HER2/neu] was detected with progressive increases in standardized total immunoglobulin-equivalent concentrations formulated at 0.010, 0.025, 0.050, 0.250, and 0.500 μg IgG/ml (Figure 3). The cell-ELISA profiles served to validate the retained selective binding-avidity of gemcitabine-(C₄-amide)-[anti-HER2/neu] for HER2/neu receptor sites highly over-expressed at 1 x 10⁶/cell on the exterior surface membrane of mammary adenocarcinoma (SKBr-3) populations (Figure 3) [20].

Cytotoxic anti-neoplastic potency analysis

Gemcitabine-(C₄-amide)-[anti-HER2/neu] exerted a 41.1% maximum level of selective "targeted" cytotoxic anti-neoplastic potency (58.9% residual survival) against chemotherapeutic-resistant mammary adenocarcinoma (SKBr-3) at a gemcitabine-equivalent concentration of 10⁻⁴ M with progressive increases from 14% to 41.1% (86.0% and 58.9% residual survival) detected between 10⁻⁸ M and 10⁻⁶ M respectively over a direct-contact incubation period of 182-hours (Figure 4).

Cytotoxic anti-neoplastic potency profiles for gemcitabine-(C₄-amide)-[anti-HER2/neu] after a 182-hour direct-contact incubation period were highly analogous to gemcitabine chemotherapeutic following a 72-hour direct-contact incubation period at the
gemcitabine-equivalent concentrations of 10⁻⁴, 10⁻³, 10⁻² and 10⁻¹ M (Figure 4). Gemcitabine alone at 182-hours produced rapid increases in cytotoxic anti-neoplastic potency from 5.8% to 88.3% (94.2% and 11.7% residual survival) at and between the gemcitabine-equivalent concentrations of 10⁻⁴ M and 10⁻² M respectively (Figure 4). Maximum cytotoxic anti-neoplastic potency for gemcitabine was 92.5% (7.5% residual survival) at the gemcitabine-equivalent concentration of 10⁻² M (Figure 4). Cytotoxic anti-neoplastic potency for gemcitabine (C₆-amide)-[anti-HER2/neu] was detectably lower based on observed values of 27.3% and 40.1% (72.7% and 58.9% residual survival) at 10⁻³ M and 10⁻² M respectively (Figure 4) [20].

Monoclonal anti-HER2/neu immunoglobulin fractions alone did not exert detectable levels of ex vivo cytotoxic anti-neoplastic potency against chemotherapeutic-resistant mammary adenocarcinoma (SKBr-3) which is in direct accord with descriptions from previous investigations for anti-HER2/neu [40,44,47-51] and anti-EGFR [44] at 0-to-182 hours in populations of several different neoplastic cell types (Figure 4).

The benzimidazole tubulin/microtubule inhibitors, albendazole, flubendazole and mebendazole exerted substantial cytotoxic anti-neoplastic potency against chemotherapeutic-resistant mammary adenocarcinoma (SKBr-3) over direct-contact incubation periods of both 72-hours and 182-hours when formulated in triplicate at final concentrations ranging between 0.05 µM to 2.5 µM (Figures 5-7). The benzimidazoles, flubendazole and mebendazole exerted near maximum levels of cytotoxic anti-neoplastic potencies of 70.2% and 63.1% (29.8% and 36.8% residual survival) at the final concentration of 0.4 µM in contrast to albendazole which reached only a level of 6.2% (93.8% residual survival) at this same benzimidazole-equivalent concentration (Figure 6). Flubendazole produced a rapid increase in cytotoxic anti-neoplastic activity from 0.0% to 70.2% (100.0% and 29.8% residual survival) at and between the benzimidazole concentrations of 0.05 µM and 0.4 µM while mebendazole produced rapid increases in cytotoxic anti-neoplastic activity from 0.1% to 63.1% (99.9% and 36.9% residual survival) at and between the same benzimidazole-equivalent concentrations of 0.05 µM and 0.5 µM respectively (Figure 6). In marked contrast, albendazole produced progressive increases in cytotoxic anti-neoplastic activity from 6.2% to 65.4% (93.8% and 34.6% residual survival) at and between the final concentrations of 0.4 µM and 2.0 µM respectively (Figure 6).

Following an incubation period of 182-hours, flubendazole and mebendazole exerted mean cytotoxic anti-neoplastic potencies of 14.5% and 12.2% (85.5% and 87.8% residual survival) which rapidly increased to near maximum levels of 90.8% and 83.9% (9.24% and 16.1% residual survival) at and between the final benzimidazole-equivalent concentrations of 0.10 µM and 0.3 µM respectively (Figure 7). In contrast, the mean cytotoxic anti-neoplastic potency for albendazole first progressively and then rapidly increased from 9.8% to 91.0% (90.2% and 9.0% residual survival) at and between the final benzimidazole-equivalent concentrations of 0.4 µM and 2.0 µM respectively (Figure 7). Albendazole, flubendazole and mebendazole all produced maximum levels of cytotoxic anti-neoplastic potencies of 91.0%, 90.8% and 91.2% (9.0%, 9.2% and 8.8% residual survival) respectively (Figure 7).
at the final benzimidazole-equivalent concentration of 2.0 µM respectively (Figure 7). Increased duration of challenge (direct contact incubation) for the benzimidazoles with chemotherapeutic-resistant mammary adenocarcinoma (SKBr-3) populations resulted in detectably larger increases in anti-neoplastic cytotoxicity (Figures 6-8).

The cytotoxic anti-neoplastic potency of gemcitabine-(C2-amine)-[anti-HER2/neu] was markedly increased when chemotherapeutic-resistant mammary adenocarcinoma (SKBr-3) populations were challenged with the covalent immunochemotherapeutic in dual combination with mebendazole (0.15 µM fixed-concentration) at and between the gemcitabine-equivalent concentrations of 10^4 M and 10^6 M (Figures 9 and 10). Gemcitabine-(C2-amine)-[anti-HER2/neu] in dual combination with mebendazole (0.15 µM fixed final concentration) compared to gemcitabine-(C2-amine)-[anti-HER2/neu] alone each produced progressive and relatively rapid increases in cytotoxic anti-neoplastic potency from 24.2% and 10.2% (75.8% and 89.8% residual survival) to maximum levels of 68.8% and 41.1% (31.2% and 58.9% residual survival) at and between the gemcitabine-equivalent concentrations of 10^4 M and 10^6 M respectively (Figure 9). The cytotoxic anti-neoplastic potency profiles for gemcitabine-(C2-amine)-[anti-HER2/neu] compared to gemcitabine alone where substantially different when they were each applied in dual combination with mebendazole (0.15 µM fixed-concentration) between the gemcitabine-equivalent concentrations of 10^4 to 10^6 M (Figures 9 and 10). Gemcitabine-(C2-amine)-[anti-HER2/neu] in dual combination with mebendazole (0.15 µM fixed-concentration) produced progressive increases in cytotoxic anti-neoplastic potency from 24.2% to a maximum of 68.8% (75.8% and 31.2% residual survival) between the gemcitabine-equivalent concentrations of 10^4 M and 10^6 M respectively (Figures 9 and 10). Conversely, gemcitabine in dual combination with mebendazole (0.15 µM fixed-concentration) produced a rapid increase in cytotoxic anti-neoplastic potency from 33.2% to a maximum of 88.2% (66.8% and 11.8% residual survival) at the gemcitabine-equivalent concentrations of 10^4 M and 10^6 M respectively (Figures 9 and 10). Gemcitabine with mebendazole was much more potent than gemcitabine-(C2-amine)-[anti-HER2/neu] with mebendazole at gemcitabine-equivalent concentrations of 10^4 and 10^6 M producing cytotoxic anti-neoplastic potency levels of 88.2% and 90.1% (11.8% and 9.9% residual survival) compared to 32.4% and 50.8% (67.6% and 49.2% residual survival) at the gemcitabine-equivalent concentrations of 10^4 M and 10^6 M respectively (Figure 10). Mean maximum cytotoxic anti-neoplastic potencies for gemcitabine-(C2-amine)-[anti-HER2/neu] with mebendazole compared to gemcitabine with mebendazole were 68.8% and 88.7% (31.2% and 11.3% residual survival) respectively at the gemcitabine-equivalent concentration of 10^6 M (Figure 10).

Gemcitabine-(C2-amine)-[anti-HER2/neu] in dual combination with mebendazole (0.15 µM fixed-concentration) produced greater

---

**Figure 7:** Relative cytotoxic anti-neoplastic potency of benzimidazoles against chemotherapeutic-resistant mammary adenocarcinoma (SKBr-3). Legends: (●) albendazole; (▲) flubendazole; and (◆) mebendazole. Chemotherapeutic-resistant mammary adenocarcinoma (SKBr-3) monolayer populations were incubated for 182-hours with the benzimidazole tubulin/microtubule inhibitors formulated in triplicate at gradient molar-equivalent concentrations. Cytotoxic anti-neoplastic potency was measured using a MTT cell vitality assay relative to matched negative reference controls.

**Figure 8:** Relative cytotoxic anti-neoplastic potency of benzimidazoles against chemotherapeutic-resistant mammary adenocarcinoma (SKBr-3). Legends: (●) albendazole; (▲) flubendazole; and (◆) mebendazole. Chemotherapeutic-resistant mammary adenocarcinoma (SKBr-3) monolayer populations were incubated for 182-hours with the benzimidazole tubulin/microtubule inhibitors formulated in triplicate at gradient molar-equivalent concentrations. Cytotoxic anti-neoplastic potency was measured using a MTT cell vitality assay relative to matched negative reference controls.

**Figure 9:** Influence on the cytotoxic anti-neoplastic potency of gemcitabine-(C2-amine)-[anti-HER2/neu] when applied in dual combination with mebendazole against chemotherapeutic-resistant human mammary adenocarcinoma. Legends: (●) covalent gemcitabine-(C2-amine)-[anti-HER2/neu] immunochemotherapeutic and mebendazole; (▲) covalent gemcitabine-(C2-amine)-[anti-HER2/neu] immunochemotherapeutic; and (◆) gemcitabine with mebendazole Chemotherapeutic-resistant mammary adenocarcinoma (SKBr-3) monolayer populations were incubated with gemcitabine-(C2-amine)-[anti-HER2/neu] formulated in triplicate at gradient concentrations (+/- mebendazole 0.15 µM fixed-concentration). Cytotoxic anti-neoplastic potency was measured using a MTT cell vitality assay relative to matched negative reference controls.
levels of cytotoxic anti-neoplastic potency compared to gemcitabine alone at gemcitabine-equivalent concentrations of $10^{-10}$ M and $10^{-9}$ M, nearly equivalent levels at $10^{-8}$ M but lower levels at $10^{-7}$ M and $10^{-6}$ M respectively (Figure 10). Cytotoxic anti-neoplastic potency of gemcitabine-($C_4$-amide)-[anti-HER2/neu] in dual combination with mebendazole (0.15 µM fixed-concentration) progressively increased from 24.2% to 61.8% (75.8% to 31.2% residual survival) at and between the gemcitabine-equivalent concentrations of $10^{-8}$ and $10^{-7}$ M (Figure 10). In contrast, gemcitabine alone produced rapid increases in cytotoxic anti-neoplastic potency from 5.8% to 88.3% (94.2% to 11.7% residual survival) between the gemcitabine-equivalent concentrations of $10^{-6}$ M and $10^{-5}$ M respectively (Figure 10). Compared to gemcitabine-($C_4$-amide)-[anti-HER2/neu] in dual combination with mebendazole (0.15 µM fixed-concentration), gemcitabine alone had greater cytotoxic anti-neoplastic potencies of 88.3% versus 50.8% (11.7% and 49.2% residual survival) and maximum levels of 92.5% versus 68.8% (7.5% and 31.2% residual survival) at the gemcitabine-equivalent concentrations of $10^{-7}$ M and $10^{-6}$ M respectively (Figure 10).

Gemcitabine in dual combination with mebendazole (0.15 µM fixed-concentration) had a cytotoxic anti-neoplastic potency profile that was distinctly greater than detected for gemcitabine alone at the gemcitabine-equivalent concentrations of $10^{-10}$ M, $10^{-9}$ M and $10^{-8}$ M but not at $10^{-7}$ M or $10^{-6}$ M (Figure 10). Gemcitabine in dual combination with mebendazole (0.15 µM fixed-concentration) produced progressive and then rapid increases in cytotoxic anti-neoplastic potency from 30.3% to 88.2% (69.7% to 11.8% residual survival) at and between the gemcitabine-equivalent concentrations of $10^{-9}$ M and $10^{-8}$ M respectively (Figure 10). Similarly, gemcitabine alone created progressive and then rapid increases in cytotoxic anti-neoplastic potency from 5.6% to 88.3% (94.4% and 11.7% residual survival) at and between the gemcitabine-equivalent concentrations of $10^{-8}$ M and $10^{-7}$ M respectively (Figure 10). Gemcitabine in dual combination with mebendazole (0.15 µM fixed-concentration) was substantially more potent than gemcitabine alone at the gemcitabine-equivalent concentrations of $10^{-8}$ M (30.3% versus 5.6%), $10^{-7}$ M (28.3% versus 5.8%), $10^{-6}$ M (88.2% versus 24.3%) respectively (Figure 10). Mean maximum cytotoxic anti-neoplastic potencies for gemcitabine in dual combination with mebendazole (0.15 µM fixed-concentration) compared to gemcitabine alone were nearly identical at 90.1% versus 88.32 (9.9% and 11.7% residual survival) and 88.7% versus 92.5% (11.3% and 7.5% residual survival) at the gemcitabine-equivalent concentrations of $10^{-7}$ M and $10^{-6}$ M respectively (Figure 10).

Discussion

General

The molecular design and implementation of succinimidyl 4,4-azipentanoate in organic chemistry reactions schemes to create the UV-photoactivated gemcitabine-($C_4$-amide) intermediate for the synthesis of gemcitabine-($C_4$-amide)-[anti-HER2/neu] [40] or other covalent gemcitabine immunochemotherapeutics has not been extensively delineated to date. Somewhat analogous organic chemistry reaction schemes for the synthetic production of a covalent gemcitabine-($C_4$-methylhydroxy)-[anti-HER2/neu] immunochemotherapeutic have been described in a limited number of investigations [20]. Gemcitabine-($C_4$-amide)-[anti-HER2/neu] and the organic chemistry reactions utilized in the corresponding synthesis scheme offer several distinct advantages including gentler reaction conditions, greater retained biological activity (IgG binding avidity), greater end-product yield (due to less IgG degradation or polymerization), flexibility of prolonged storage of the UV-photoactivated chemotherapeutic intermediate, and implementation of a covalent bond forming moiety that lacks any aeryometric structure which is known to decrease the probability of inducing humor immune responses.

Cytotoxic anti-neoplastic potency

Increases in the molar chemotherapeutic-equivalent concentrations of gemcitabine-($C_4$-amide)-[anti-HER2/neu] created declines in the survival of chemotherapeutic-resistant mammary adenocarcinoma (SKBr-3) populations (Figures 4 and 9). Cytotoxic anti-neoplastic potency of gemcitabine-($C_4$-amide)-[anti-HER2/neu] against chemotherapeutic-resistant mammary adenocarcinoma (SKBr-3) following an incubation period of 182-hours was very similar to gemcitabine alone after a shorter 72-hour incubation period (Figure 4). Gemcitabine-($C_4$-amide)-[anti-HER2/neu] at the gemcitabine-equivalent concentrations of $10^{-7}$ M or $10^{-6}$ M during a 182-hour incubation period did not exert a substantially greater degree of selectively “targeted” anti-neoplastic potency against chemotherapeutic-resistant mammary adenocarcinoma (SKBr-3) compared to gemcitabine alone (Figures 4, 9 and 10). Such findings are in contrast to the measurably greater or equivalent levels of cytotoxic anti-neoplastic potency of covalent epirubicin-[anti-HER2/neu] immunochemotherapeutics compared to epirubicin alone [41-44]. Despite this difference, results imply that greater levels of selectively “targeted” cytotoxic anti-neoplastic potency could have been attained with gemcitabine-($C_4$-amide)-[anti-HER2/neu] at incubation periods of duration greater than 182-hours (Figure 4).

Conceptually there are at least five analytical variables that could...
have alternatively been modified to achieve substantially higher total levels of cytotoxic anti-neoplastic potency for gemcitabine-(C$_{6}$-amide)-[anti-HER2/neu]. First, incubation times with chemotherapeutic-resistant mammary adenocarcinoma (SKBr-3) could have been lengthened to a period >182-hours [19] thereby allowing greater opportunity for larger amounts of gemcitabine to be internalized by receptor-mediated endocytosis and subsequently liberated intracellularly from gemcitabine-(C$_{6}$-amide)-[anti-HER2/neu]. Support for this consideration is based on the observation that there was a simple dose effect for gemcitabine-(C$_{6}$-amide)-[anti-HER2/neu] and, because mammary adenocarcinoma (SKBr-3) survival was very similar when challenged with either gemcitabine-(C$_{6}$-methylcarbamate)-[anti-HER2/neu] [20] or gemcitabine-(C$_{4}$-amide)-[anti-HER2/neu] (182 hours) compared to gemcitabine (72-hours), which then increased dramatically for gemcitabine over an extended incubation period (182 hours) (Figures 4, 9 and 10) [20].

Second, cytotoxic anti-neoplastic potency of gemcitabine-(C$_{6}$-amide)-[anti-HER2/neu] could alternatively have been assessed against a non-chemotherapeutic-resistant human neoplastic cell type similar to those utilized to evaluate majority of the covalent biochemotherapeutics reported in the literature to date. Similarly, the cytotoxic anti-neoplastic potency of gemcitabine-(C$_{6}$-amide)-[anti-HER2/neu] could also have alternatively been measured against an entirely different neoplastic cell type such as pancreatic carcinoma [32] small-cell lung carcinoma [53] neuroblastoma, [54] or leukemia/lymphoid [55,56] due to their relatively higher gemcitabine sensitivity. In addition, human promyelocytic leukemia [24,55], T-4 lymphoblastoid clones [55], glioblastoma [24,55], cervical epitheloid carcinoma [55], colon adenocarcinoma [55], pancreatic adenocarcinoma [55], pulmonary adenocarcinoma [55], oral squamous cell carcinoma [55], and prostatic carcinoma [57] have been found to be sensitive to gemcitabine and gemcitabine-(oxetahydrophipolid) chemotherapeutic conjugates. Presumably this pattern of gemcitabine sensitivity is directly relevant to the cytotoxic anti-neoplastic potency detected for gemcitabine-(C$_{6}$-amide)-[anti-HER2/neu] in chemotherapeutic-resistant mammary adenocarcinoma (SKBr-3) populations (Figure 4).

Third, [3H]-thymidine, or an ATP-based assay could have alternatively been applied to measure anti-neoplastic potency of gemcitabine-(C$_{6}$-amide)-[anti-HER2/neu] since they are reportedly >10-fold more sensitive in detecting early sub-lethal cell injury compared to MITT vitality stain assay methods [58,59]. Despite this consideration, MITT vitality stain continues to be extensively applied for the routine assessment of true cytotoxic anti-neoplastic potency in contrast to transient or sub-lethal injury for chemotherapeutics covalently incorporated synthetically into molecular platforms that provide properties of selective “targeted” delivery [24,44,55,60-66]. In this context, one distinctly important attribute of MITT vitality stain based assays is that they provide a way of measuring the extent of cell death induced by an anti-cancer agent within a population of neoplastic cells in a manner that tends to have greater relevance to clinical oncology in contrast to assays for biomarkers that simply reflect transient (non-lethal) cell injury.

Fourth, cytotoxic anti-neoplastic potency of gemcitabine-(C$_{6}$-amide)-[anti-HER2/neu] immunochemothperapy could have been delineated in-vivo against human neoplastic xenographs in animal hosts as a model for human cancer. Many if not most covalent immunochemotherapeutics with properties of selective “targeted” delivery frequently have a higher degree of effectiveness and potency when evaluated in-vivo in contrast to levels acquired ex-vivo in tissue culture models utilizing the same cancer cell type [67-69]. Enhanced efficacy and potency is in part attributable to endogenous immune responses including antibody-dependent cell cytotoxicity (ADCC) phenomenon [70] in concert with complemented-mediated cytolysis induced by formation of antigen-immunoglobulin complexes on the external surface membrane of “targeted” neoplastic cell populations. During ADCC events cytotoxic components are liberated that additively and synergistically enhance the cytotoxic anti-neoplastic activity of conventional chemotherapeutic agents [71]. Contributions of ADCC and complement-mediated cytolysis to the in-vivo cytotoxic anti-neoplastic potency of covalent immunochemotherapeutics is further complemented by the additive and synergistic anti-neoplastic properties attained with anti-epidermal growth factor monoclonal immunoglobulin when applied in dual combination with conventional chemotherapeutic agents [72-83]. Additive or synergistic interactions of this type have been delineated between anti-HER2/neu when applied simultaneously with cyclophosphamide [79,81], docetaxel [79], doxorubicin [79,81], etoposide [79], methotrexate [79], paclitaxel [79,81] or vinblastine [79].

Fifth, strategies for the synthesis of gemcitabine-(C$_{6}$-amide)-[anti-HER2/neu] could have been modified to increase the gemcitabine molar-incorporation-index. Unfortunately, such modifications usually require the implementation of harsher reaction conditions that in turn impose a higher risk of reduced biological activity (e.g. IgG antigen binding avidity) and substantial declines in final/total product yield [69,84]. Aside from overly harsh synthesis conditions, excessively high molar incorporation indexes for any chemotherapeutic agent can also reduce biological integrity of immunoglobulin fractions when the number of pharmaceutical groups introduced into the Fab’ antigen-binding identity and substantial declines in final/total product yield [69,84]. Aside from overly harsh synthesis conditions, excessively high molar incorporation indexes for any chemotherapeutic agent can also reduce biological integrity of immunoglobulin fractions when the number of pharmaceutical groups introduced into the Fab’ antigen-binding identity and substantial declines in final/total product yield [69,84]. Aside from overly harsh synthesis conditions, excessively high molar incorporation indexes for any chemotherapeutic agent can also reduce biological integrity of immunoglobulin fractions when the number of pharmaceutical groups introduced into the Fab’ antigen-binding identity and substantial declines in final/total product yield [69,84]. Aside from overly harsh synthesis conditions, excessively high molar incorporation indexes for any chemotherapeutic agent can also reduce biological integrity of immunoglobulin fractions when the number of pharmaceutical groups introduced into the Fab’ antigen-binding identity and substantial declines in final/total product yield [69,84]. Aside from overly harsh synthesis conditions, excessively high molar incorporation indexes for any chemotherapeutic agent can also reduce biological integrity of immunoglobulin fractions when the number of pharmaceutical groups introduced into the Fab’ antigen-binding identity and substantial declines in final/total product yield [69,84]. Aside from overly harsh synthesis conditions, excessively high molar incorporation indexes for any chemotherapeutic agent can also reduce biological integrity of immunoglobulin fractions when the number of pharmaceutical groups introduced into the Fab’ antigen-binding identity and substantial declines in final/total product yield [69,84]. Aside from overly harsh synthesis conditions, excessively high molar incorporation indexes for any chemotherapeutic agent can also reduce biological integrity of immunoglobulin fractions when the number of pharmaceutical groups introduced into the Fab’ antigen-binding identity and substantial declines in final/total product yield [69,84]. Aside from overly harsh synthesis conditions, excessively high molar incorporation indexes for any chemotherapeutic agent can also reduce biological integrity of immunoglobulin fractions when the number of pharmaceutical groups introduced into the Fab’ antigen-binding identity and substantial declines in final/total product yield [69,84]. Aside from overly harsh synthesis conditions, excessively high molar incorporation indexes for any chemotherapeutic agent can also reduce biological integrity of immunoglobulin fractions when the number of pharmaceutical groups introduced into the Fab’ antigen-binding identity and substantial declines in final/total product yield [69,84]. Aside from overly harsh synthesis conditions, excessively high molar incorporation indexes for any chemotherapeutic agent can also reduce biological integrity of immunoglobulin fractions when the number of pharmaceutical groups introduced into the Fab’ antigen-binding identity and substantial declines in final/total product yield [69,84]. Aside from overly harsh synthesis conditions, excessively high molar incorporation indexes for any chemotherapeutic agent can also reduce biological integrity of immunoglobulin fractions when the number of pharmaceutical groups introduced into the Fab’ antigen-binding identity and substantial declines in final/total product yield [69,84]. Aside from overly harsh synthesis conditions, excessively high molar incorporation indexes for any chemotherapeutic agent can also reduce biological integrity of immunoglobulin fractions when the number of pharmaceutical groups introduced into the Fab’ antigen-binding identity and substantial declines in final/total product yield [69,84].
Cytotoxic anti-neoplastic potency of tubulin/microtubule inhibitors

**Benzimidazole literature review:** The benzimidazole class of anthelmintics within neoplastic cells exert a mechanism-of-action that is distinctly different, but still similar to that of the vinca alkaloids [89] which involves binding to colchicine-sensitive sites on β-tubulin protein. The ultimate effect is an inhibition of tubulin polymerization or induced tubulin de-polymerization with subsequent suppression of normal microtubule assembly and function necessary for successful completion of mitosis (cell cycle M-phase). Coincident with a disruption of mitosis, benzimidazole tubulin/microtubule inhibitors are believed to induce apoptosis in neoplastic cells through a variety of pathways based upon detection of elevations in Bcl-2 phosphorylation [90], capase-3, [91-94] capase-8 [94], capase-9 [92,94], cytochrome-C release [91,92,94,95], p53 [92], DNA laddering profiles [93] and DNA fragmentation (TUNEL) [93,94]. Declines in neoplastic cell growth and viability induced by benzimidazole tubulin/microtubule inhibitors have been detected as a function of alterations in parameters that reflect G1/M [93,94,96] and G2/G1 [96] arrest, decreased [1H]thymidine incorporation [96] spheroid cell formation [92], altered cell vitality staining intensity [94], and suppression of growth kinetics [93]. Benzimidazoles also inhibit vascular endothelial growth factor receptor function (VEGFR) [97], and reduce expression of CD31 (tumor angiogenesis biomarker) [92,95], carcinoembryonic antigen (CEA: in-vivo) [98]; and α-feto protein (AFP: in-vivo) [98].

The ultimate effect of benzimidazoles on cancer cell biology includes their ability to promote suppress migration/invansion (in vitro) [92], metastasis (in-vivo) [92,95], and tumor growth rate (in-vivo) [95]. Preliminary experimental investigations have detected vulnerability of adenocortical carcinoma (xenographs) [92], colorectal cancer [93,98], hepatocellular carcinoma [96,98], leukemia [89,91], lung cancer [95], (non-small cell [94,95]), melanoma (chemo-resistant) [90], myeloma [89], and ovarian cancer [96,97,99,100] to benzimidazole tubulin/microtubule inhibitors. The cytotoxic anti-neoplastic potency of the benzimidazole class of tubulin/microtubule inhibitors against breast cancer has previously remained largely unknown. In contrast to a single report for flubendazole, the creation of mammalian chromosomal aberrations has to date been described for either albendazole [93,97] or mebendazole [101].

**Benzimidazole laboratory results:** In chemotherapeutic-resistant mammary adenocarcinoma (SKBr-3) the benzimidazole tubulin/microtubule inhibitors albendazole, mebendazole and flubendazole each demonstrated detectable cytotoxic anti-neoplastic potency between a final concentration range of 0 µM to 2.5 µM that was similar to levels observed against other neoplastic cell types (Figures 6-8) [89-94]. Cytotoxic anti-neoplastic potencies for albendazole, flubendazole and mebendazole increased when the direct-contact incubation period was extended from 72-hours to 182 hours (Figures 6, 7 and 8). Flubendazole was the most potent benzimidazole while albendazole was substantially less potent than either flubendazole or mebendazole against chemotherapeutic-resistant mammary adenocarcinoma (SKBr-3) at benzimidazole-equivalent concentrations below 0.75 mM (Figures 6 and 7). The relative order of benzimidazole cytotoxic anti-neoplastic potency against chemotherapeutic-resistant mammary adenocarcinoma (SKBr-3) closely correlates with profiles recognized with other neoplastic cell types including leukemia [89] and myeloma [89] cell types at longer incubation periods (Figures 6 and 7) [40,41].

**Dual combination cytotoxic anti-neoplastic potencies:** The mechanism-of-action for the benzimidazoles is similar to the vinca alkaloids, taxanes (e.g. paclitaxel), podophyllotoxins (e.g. etoposide) and monomethyl auristatin E (MMAE). Based on these properties speculation suggests that benzimidazoles can additively or synergistically enhance the cytotoxic anti-neoplastic potency of conventional and selectively “targeted” chemotherapeutics. Such properties to date have largely remained unknown except for limited preliminary descriptions for dual vinblastine/benzimidazole combinations [89].

Significantly greater levels of cytotoxic anti-neoplastic potency were attained with gemcitabine-(C<sub>9</sub>-amide)-[anti-HER2/neu] immunochemotherapeutic or gemcitabine alone when applied in dual combination with the mebendazole (Figures 9 and 10). Covalent gemcitabine-(C<sub>9</sub>-amide)-[anti-HER2/neu] immunochemotherapeutic in dual combination with mebendazole (0.15 µM fixed-concentration) exerted significantly greater levels of cytotoxic anti-neoplastic potency than gemcitabine-(C<sub>9</sub>-amide)-[anti-HER2/neu] alone between the gemcitabine-equivalent concentrations of 10<sup>-8</sup> M and 10<sup>-6</sup> M (Figure 9). Maximum cytotoxic anti-neoplastic potency of gemcitabine-(C<sub>9</sub>-amide)-[anti-HER2/neu] in combination with mebendazole (0.15 µM fixed-concentration) 68.8% (31.2% residual survival) was detected at the gemcitabine-equivalent concentration of 10<sup>-6</sup> M (Figure 9). Gemcitabine in combination with mebendazole (0.15 µM fixed-concentration) was more potent than gemcitabine-(C<sub>9</sub>-amide)-[anti-HER2/neu] in combination with mebendazole (0.15 µM fixed-concentration) and this trend was most prominent at the gemcitabine-equivalent concentrations of 10<sup>-4</sup> M, 10<sup>-3</sup> M, and 10<sup>-2</sup> M (Figure 10). Gemcitabine chemotherapeutic alone compared to gemcitabine-(C<sub>9</sub>-amide)-[anti-HER2/neu] in combination with mebendazole (0.15 µM fixed-concentration) both exerted somewhat similar profiles for cytotoxic anti-neoplastic potency within the lower gemcitabine-equivalent concentrations at and between 10<sup>-5</sup> M and 10<sup>-4</sup> M (Figure 10). Gemcitabine alone tended to be more potent at the higher gemcitabine-equivalent concentrations of 10<sup>-3</sup> M (88.3% -versus- 50.8%) and 10<sup>-4</sup> M (92.5% -versus- 68.8%) respectively (Figure 10).

The cytotoxic anti-neoplastic potency profiles for mebendazole when applied in dual combination with a covalent gemcitabine-(C<sub>9</sub>-amide)-[anti-HER2/neu] or gemcitabine illustrates the potential of the benzimidazoles to complement the efficacy of gemcitabine and covalent gemcitabine immunochemotherapeutics (Figures 9 and 10). In direct correlation with these findings, benzimidazoles also (additively or synergistically) complement the cytotoxic anti-neoplastic potency of epirubicin and covalent epirubicin immunochemotherapeutics against chemotherapeutic-resistant mammary adenocarcinoma (SKBr-3) [41]. Undoubtedly, levels of cytotoxic anti-neoplastic potency for gemcitabine-(C<sub>9</sub>-amide)-[anti-HER2/neu] immunochemotherapeutic in dual combination with mebendazole (0.15 µM fixed-concentration) would probably be measurably greater with the implementation of direct-contact incubation periods longer than 182-hours.

**Conclusion**

Organic chemistry reaction schemes have been developed to facilitate synthesis of gemcitabine-(C<sub>9</sub>-amide)-[anti-HER2/neu] that possesses properties of selective “targeted” delivery that can also serve as a prototype or reference template for the molecular
design and organic chemistry synthesis of similar covalent immunochemotherapeutic or ligand-chemotherapeutics. Attributes of the synthesis method include; [i] greater flexibility for conveniently covalently bonding gemcitabine and other chemotherapeutics with analogous chemical properties and molecular structure to large molecular weight platforms at a relatively high chemotherapeutic molar incorporation index; [ii] affords a lower risk of spontaneous immunoglobulin polymerization compared to synthesis methods dependent on protein pre-thiolation; [iii] utilization of synthesis conditions during covalent bond formation that impose a lower risk of promoting degradative fragmentation or large molecular weight polymerization; [iv] design and synthesis of covalent chemotherapeutic-ligands or immunochemotherapeutics that can employ a spectrum of large molecular weight platforms that possess an array of different selective “targeted” delivery properties; and an [v] option to generate a reactive chemotherapeutic intermediate that can be stored for prolonged periods for future application.

Cytotoxic anti-neoplastic potencies for gemcitabine-(C₇-amide)-[anti-HER2/neu] at the end of a 182-hour incubation period were similar to gemcitabine following a 72-hour incubation period in populations of chemotherapeutic-resistant mammary adenocarcinoma (SKBr-3). Cytotoxic anti-neoplastic potency of gemcitabine-(C₇-amide)-[anti-HER2/neu] would likely have been greater if it had been evaluated using an incubation period greater than 182-hours or had been determined against human promyelocytic leukemia, T-4 lymphoblastoid clones, glioblastoma; cervical epithelial carcinoma, colon adenocarcinoma, pancreatic adenocarcinoma, pulmonary adenocarcinoma, oral squamous cell carcinoma, or prostatic carcinoma. Parallel investigations delineated the relative cytotoxic anti-neoplastic potency of the benzimidazole tubulin/microtubule inhibitors, albendazole, flubendazole, and mebendazole against chemotherapeutic-resistant mammmary adenocarcinoma (SKBr-3). Mebendazole in dual combination with gemcitabine or gemcitabine-(C₇-amide)-[anti-HER2/neu] resulted in levels of cytotoxic anti-neoplastic potency that were greater than those obtained with either gemcitabine or gemcitabine-(C₇-amide)-[anti-HER2/neu] respectively.

Discovery and preliminary characterization of the cytotoxic anti-neoplastic properties of gemcitabine-(C₇-amide)-[anti-HER2/ neu] and benzimidazoles in addition to the enhanced levels of efficacy achieved with dual combinations against chemotherapeutic-resistant mammary adenocarcinoma (SKBr-3) has several important implications. Such dual combinations offers the potential option for developing treatment schemes that more rapidly evoke durable (long-term) resolution of neoplastic disease states that are at least in part attainable because both the benzimidazoles [102-104] and chemotherapeutics covalently bound to large molecular weight platforms are apparently poor substrates for P-glycoprotein/MDR-1 (multi-drug resistance efflux pump) [24,105]. Accompanying their potential to effectively resolve neoplastic conditions, covalent gemcitabine immunochemotherapeutics, gemcitabine or other conventional chemotherapeutic agents in dual additive or synergistic combination with benzimidazoles represent a therapeutic regimen option for implementation in clinical oncology that may have a relatively wide safety index due to of fewer and less severe sequelae. Conceptually, such attributes collectively can at least theoretically be attained because of the relatively wide safety index for both the benzimidazoles compared to many if not most conventional chemotherapeutics [93,98,99,106] in addition to the selective “targeted” delivery properties of covalent immunochemotherapeutics. Collectively each of these attributes can contribute to realizing enhanced levels of cytotoxic anti-neoplastic potency which can ultimately facilitate both a more rapid resolution of neoplastic conditions and a lowering of total chemotherapeutic dosage requirements can further reduce the frequency and severity of sequelae plus decrease the probability of resistance developing during prolonged administration protocols. Lastly, from a clinical oncology perspective, the application of either a covalent gemcitabine immunochemotherapeutic or gemcitabine in dual combination with benzimidazole tubulin/microtubule inhibitors directly coincides with the general recommendation for in-vivo treatment regimens. Such guidelines in part advocate administration of different anti-cancer agent classes during the course of multi-chemotherapeutic regimens that ideally exert different mechanisms-of-action (avoids competitive inhibition) and individually precipitate distinctly different sets of undesirable sequelae.

Conflict of Interest

Source of Research Support: residual extramural funding from the conduction of a previous un-related research investigation.

Acknowledgements

The authors would like to acknowledge Mr. Tom Thompson in the Office of Agriculture Communications for assistance with the photographic illustration.

References


**Author Affiliations**

1Department of Basic Sciences (College of Veterinary Medicine), Mississippi State University, USA
2College of Veterinary Medicine at Wise Center, Mississippi State University, USA

Submit your next manuscript at [www.scitechnol.com/submission](http://www.scitechnol.com/submission)